The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims https://t.co/vxa05r0GvS

#ACR22 Abstr#0359 Is 2021 DORIS remission attainable in #lupus? Pooled analyses of Anifrolumab RCTs showed this was met in ~10% patients in treatment group vs 3% placebo. Faster and sustained too @Rheumnow https://t.co/5MY2O8i2gA https://t.co/PUeUY25JZl

#ACR22 Raynaud’s: 💡Primary RP is the most common 💡Autoimmune RP is rare! Other causes more common: metabolic, trauma, vibration, Buergers. 💡NMA showed that both CCB and PDE5i reduced frequency and severity of symptoms 💡Supportive measures are cornerstone! @ACRheum @RheumNow https://t.co/tb5FEmHJDz

“For the secret of the care of the patient is in caring for the patient” - Francis W Peabody What a poignant end to a fantastic key note speech by Dr Abraham Verghese! #ACR22 @RheumNow https://t.co/R6Z1h8em7n

"One more thing you need in a story-- Epiphany, where the soul of the commonest object seems radiant" - Dr. Verghese. His #epiphany occurred in the #HIV era helping a dying patient come to terms w/death; he discovered “The doctor can heal without curing.” #ACR22 @rheumnow https://t.co/Yh3SU4AMIZ

GCA with visual symptoms: do you hit the pulse iv methylpred button? Why? 260 pts from Lund 🇸🇪 no doubt some channelling, but: IVMP no better and more steroid exposure/toxicity This adds to existing doubts. Time to seriously question this practice? ABST0459 #ACR22 @RheumNow https://t.co/nbQlhvoRQP

Many hoped rituximab would be the panacea for all with IgG4-RD. Consistent story: it's not. In this European data: - only 56% in remission at 12m - pancreato-hepato-biliary slightly better, RPF mid-range This story isn't over. We need other options ABST0147 #ACR22 @RheumNow https://t.co/kyIYLLWM9g

Interested in this late-breaker, comparative study of secukinumab (IL17) vs adalimumab (TNF) in AxSpa No difference in radiographic progression at 1 year - in line with my perception of relative equality for these treatments Need long term data! #ACR22 @rheumnow abstr#L15 https://t.co/7EdhJsW3bq

Only 4 minutes to discuss adherence in #SLE. Implementation of discussion if <80% of meds filled. Academic docs - 20/24 used + reinforcement, validated in 17 Pts, 11/24 asked open ended ?s. Pts thought it was right timing. ?does it change behaviour- ? Abst0063 @RheumNow #ACR22 https://t.co/UQbRgw5Emj

#ACR22 opening session. Dr.Saag: 50%of rheumatologists expected to retire in the next 10 years reducing our workforce by 25%. Significant concern for access to rheum care lays ahead of us #rheumshortage @RheumNow https://t.co/ECXA2QG0kH